Annual CFF
$88.40 M
-$56.32 M-38.92%
31 December 2023
Summary:
Astria Therapeutics annual cash flow from financing activities is currently $88.40 million, with the most recent change of -$56.32 million (-38.92%) on 31 December 2023. During the last 3 years, it has risen by +$47.54 million (+116.34%). ATXS annual CFF is now -38.92% below its all-time high of $144.72 million, reached on 31 December 2022.ATXS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$15.30 M
+$15.21 M+16177.66%
30 September 2024
Summary:
Astria Therapeutics quarterly cash flow from financing activities is currently $15.30 million, with the most recent change of +$15.21 million (+16177.66%) on 30 September 2024. Over the past year, it has increased by +$15.19 million (+13810.00%). ATXS quarterly CFF is now -89.21% below its all-time high of $141.81 million, reached on 31 March 2024.ATXS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$245.18 M
+$15.19 M+6.61%
30 September 2024
Summary:
Astria Therapeutics TTM cash flow from financing activities is currently $245.18 million, with the most recent change of +$15.19 million (+6.61%) on 30 September 2024. Over the past year, it has increased by +$124.36 million (+102.94%). ATXS TTM CFF is now at all-time high.ATXS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ATXS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.9% | +10000.0% | +102.9% |
| 3 y3 years | +116.3% | +10000.0% | +135.1% |
| 5 y5 years | +99.6% | +1472.6% | +1043.5% |
ATXS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -38.9% | +116.3% | -89.2% | at high | >+9999.0% | |
| 5 y | 5 years | -38.9% | +245.0% | -89.2% | at high | >+9999.0% | |
| alltime | all time | -38.9% | +1770.5% | -89.2% | +1302.0% | at high | +7381.9% |
Astria Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $15.30 M(>+9900.0%) | $245.18 M(+6.6%) |
| June 2024 | - | $94.00 K(-99.9%) | $229.99 M(-0.1%) |
| Mar 2024 | - | $141.81 M(+61.2%) | $230.17 M(+160.4%) |
| Dec 2023 | $88.40 M(-38.9%) | $87.98 M(>+9900.0%) | $88.40 M(-26.8%) |
| Sept 2023 | - | $110.00 K(-59.7%) | $120.82 M(-16.7%) |
| June 2023 | - | $273.00 K(+637.8%) | $145.03 M(+0.2%) |
| Mar 2023 | - | $37.00 K(-100.0%) | $144.76 M(+0.0%) |
| Dec 2022 | $144.72 M(+38.8%) | $120.40 M(+395.0%) | $144.72 M(+494.6%) |
| Sept 2022 | - | $24.32 M(>+9900.0%) | $24.34 M(>+9900.0%) |
| June 2022 | - | $0.00(0.0%) | $23.00 K(0.0%) |
| Mar 2022 | - | $0.00(-100.0%) | $23.00 K(-100.0%) |
| Dec 2021 | $104.28 M(+155.2%) | $17.00 K(+183.3%) | $104.28 M(-0.0%) |
| Sept 2021 | - | $6000.00(>+9900.0%) | $104.30 M(-7.9%) |
| June 2021 | - | $0.00(-100.0%) | $113.23 M(-5.2%) |
| Mar 2021 | - | $104.26 M(>+9900.0%) | $119.50 M(+192.5%) |
| Dec 2020 | $40.86 M(+59.5%) | $31.00 K(-99.7%) | $40.86 M(-8.4%) |
| Sept 2020 | - | $8.94 M(+42.7%) | $44.60 M(+21.7%) |
| June 2020 | - | $6.26 M(-75.6%) | $36.63 M(+19.9%) |
| Mar 2020 | - | $25.62 M(+579.3%) | $30.56 M(+19.3%) |
| Dec 2019 | $25.62 M | $3.77 M(+287.7%) | $25.62 M(+19.5%) |
| Sept 2019 | - | $973.00 K(+406.8%) | $21.44 M(+11.7%) |
| June 2019 | - | $192.00 K(-99.1%) | $19.20 M(-66.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $20.68 M(-5181.8%) | $57.50 M(+29.8%) |
| Dec 2018 | $44.30 M(+837.3%) | -$407.00 K(-68.0%) | $44.30 M(-1.6%) |
| Sept 2018 | - | -$1.27 M(-103.3%) | $44.99 M(-2.3%) |
| June 2018 | - | $38.49 M(+414.6%) | $46.04 M(+326.2%) |
| Mar 2018 | - | $7.48 M(+2452.9%) | $10.80 M(+128.6%) |
| Dec 2017 | $4.73 M(-48.4%) | $293.00 K(-230.8%) | $4.73 M(+26.4%) |
| Sept 2017 | - | -$224.00 K(-106.9%) | $3.74 M(-75.7%) |
| June 2017 | - | $3.25 M(+131.9%) | $15.38 M(+35.9%) |
| Mar 2017 | - | $1.40 M(-302.2%) | $11.31 M(+23.5%) |
| Dec 2016 | $9.16 M(-88.3%) | -$694.00 K(-106.1%) | $9.16 M(+1.5%) |
| Sept 2016 | - | $11.41 M(-1510.8%) | $9.03 M(-368.3%) |
| June 2016 | - | -$809.00 K(+8.4%) | -$3.37 M(-105.5%) |
| Mar 2016 | - | -$746.00 K(-9.6%) | $60.69 M(-22.5%) |
| Dec 2015 | $78.33 M(+1520.3%) | -$825.00 K(-16.4%) | $78.33 M(-1.0%) |
| Sept 2015 | - | -$987.00 K(-101.6%) | $79.16 M(-6.8%) |
| June 2015 | - | $63.25 M(+274.5%) | $84.95 M(+291.4%) |
| Mar 2015 | - | $16.89 M(>+9900.0%) | $21.70 M(+349.0%) |
| Dec 2014 | $4.83 M(-88.3%) | $6000.00(-99.9%) | $4.83 M(+0.1%) |
| Sept 2014 | - | $4.81 M(>+9900.0%) | $4.83 M(>+9900.0%) |
| June 2014 | - | $3000.00(-84.2%) | $22.00 K(+15.8%) |
| Mar 2014 | - | $19.00 K | $19.00 K |
| Dec 2013 | $41.45 M | - | - |
FAQ
- What is Astria Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Astria Therapeutics?
- What is Astria Therapeutics annual CFF year-on-year change?
- What is Astria Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Astria Therapeutics?
- What is Astria Therapeutics quarterly CFF year-on-year change?
- What is Astria Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Astria Therapeutics?
- What is Astria Therapeutics TTM CFF year-on-year change?
What is Astria Therapeutics annual cash flow from financing activities?
The current annual CFF of ATXS is $88.40 M
What is the all time high annual CFF for Astria Therapeutics?
Astria Therapeutics all-time high annual cash flow from financing activities is $144.72 M
What is Astria Therapeutics annual CFF year-on-year change?
Over the past year, ATXS annual cash flow from financing activities has changed by -$56.32 M (-38.92%)
What is Astria Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ATXS is $15.30 M
What is the all time high quarterly CFF for Astria Therapeutics?
Astria Therapeutics all-time high quarterly cash flow from financing activities is $141.81 M
What is Astria Therapeutics quarterly CFF year-on-year change?
Over the past year, ATXS quarterly cash flow from financing activities has changed by +$15.19 M (+13810.00%)
What is Astria Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ATXS is $245.18 M
What is the all time high TTM CFF for Astria Therapeutics?
Astria Therapeutics all-time high TTM cash flow from financing activities is $245.18 M
What is Astria Therapeutics TTM CFF year-on-year change?
Over the past year, ATXS TTM cash flow from financing activities has changed by +$124.36 M (+102.94%)